Stock Track | Cardinal Health Soars 5.41% in Pre-market Trading After Strong FY2027 Profit Forecast and Q4 Earnings Beat

Stock Track08-11 21:34

Shares of Cardinal Health surged 5.41% in pre-market trading on Tuesday, driven by a fiscal 2027 profit outlook that significantly exceeded Wall Street expectations and a strong fiscal fourth-quarter earnings performance.

The company guided for full-year adjusted earnings per share of $12.40 to $12.60, representing 13% to 15% growth and handily beating the FactSet consensus estimate of $12.08. This upbeat forecast was bolstered by fiscal Q4 adjusted earnings of $2.91 per share, which topped analyst estimates of $2.42. While quarterly revenue of $63.67 billion missed the $65.03 billion consensus, the earnings strength and optimistic guidance overshadowed the top-line miss.

Additionally, the board approved a $5 billion incremental share repurchase authorization, further signaling confidence in its financial health. The company cited sustained demand for specialty drugs and biosimilars, along with growth in its pharmaceutical segment, as key drivers for the positive outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122693116?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122693116","market":"nz","top_or_hot":-1,"title":"Stock Track | Cardinal Health Soars 5.41% in Pre-market Trading After Strong FY2027 Profit Forecast and Q4 Earnings Beat","media":"Stock Track","content":"<p>Shares of Cardinal Health surged 5.41% in pre-market trading on Tuesday, driven by a fiscal 2027 profit outlook that significantly exceeded Wall Street expectations and a strong fiscal fourth-quarter earnings performance.</p>\n<p>The company guided for full-year adjusted earnings per share of $12.40 to $12.60, representing 13% to 15% growth and handily beating the FactSet consensus estimate of $12.08. This upbeat forecast was bolstered by fiscal Q4 adjusted earnings of $2.91 per share, which topped analyst estimates of $2.42. While quarterly revenue of $63.67 billion missed the $65.03 billion consensus, the earnings strength and optimistic guidance overshadowed the top-line miss.</p>\n<p>Additionally, the board approved a $5 billion incremental share repurchase authorization, further signaling confidence in its financial health. The company cited sustained demand for specialty drugs and biosimilars, along with growth in its pharmaceutical segment, as key drivers for the positive outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cardinal Health Soars 5.41% in Pre-market Trading After Strong FY2027 Profit Forecast and Q4 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cardinal Health Soars 5.41% in Pre-market Trading After Strong FY2027 Profit Forecast and Q4 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-11 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Cardinal Health surged 5.41% in pre-market trading on Tuesday, driven by a fiscal 2027 profit outlook that significantly exceeded Wall Street expectations and a strong fiscal fourth-quarter earnings performance.</p>\n<p>The company guided for full-year adjusted earnings per share of $12.40 to $12.60, representing 13% to 15% growth and handily beating the FactSet consensus estimate of $12.08. This upbeat forecast was bolstered by fiscal Q4 adjusted earnings of $2.91 per share, which topped analyst estimates of $2.42. While quarterly revenue of $63.67 billion missed the $65.03 billion consensus, the earnings strength and optimistic guidance overshadowed the top-line miss.</p>\n<p>Additionally, the board approved a $5 billion incremental share repurchase authorization, further signaling confidence in its financial health. The company cited sustained demand for specialty drugs and biosimilars, along with growth in its pharmaceutical segment, as key drivers for the positive outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAH","symbol_name":"卡地纳健康","start_time":0,"source_url":"","article_id":"1122693116","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122693116","pubTimestamp":1786455279,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Cardinal Health surged 5.41% in pre-market trading on Tuesday, driven by a fiscal 2027 profit outlook that significantly exceeded Wall Street expectations and a strong fiscal fourth-quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAH":"卡地纳健康"},"translate_title":"股票跟踪 | Cardinal Health 在 2027 财年强劲利润预测和第四季度盈利超出预期后，盘前交易中股价飙升 5.41%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAH":1},"content_text":"Shares of Cardinal Health surged 5.41% in pre-market trading on Tuesday, driven by a fiscal 2027 profit outlook that significantly exceeded Wall Street expectations and a strong fiscal fourth-quarter earnings performance.\nThe company guided for full-year adjusted earnings per share of $12.40 to $12.60, representing 13% to 15% growth and handily beating the FactSet consensus estimate of $12.08. This upbeat forecast was bolstered by fiscal Q4 adjusted earnings of $2.91 per share, which topped analyst estimates of $2.42. While quarterly revenue of $63.67 billion missed the $65.03 billion consensus, the earnings strength and optimistic guidance overshadowed the top-line miss.\nAdditionally, the board approved a $5 billion incremental share repurchase authorization, further signaling confidence in its financial health. The company cited sustained demand for specialty drugs and biosimilars, along with growth in its pharmaceutical segment, as key drivers for the positive outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122693116","isCrawlerRequest":true}